Effect of anti-epileptic drugs in pregnancy and teratogenesis

被引：3
作者：
Lakshmi S. [1 ,3 ]
Sunanda K. [2 ]
机构：
[1] Department of Biochemistry, Bangalore Medical College
[2] Department of Obstetrics and Gynecology, Bangalore Medical College
[3] Govt. Medical College, Shimoga, Karnataka
来源：
Indian Journal of Clinical Biochemistry | 2008年 / 23卷 / 3期
关键词：
Alpha feto proteins; Antiepileptic drugs; Chemiluminescence; Teratogenic effects;
D O I：
10.1007/s12291-008-0060-0
中图分类号：
学科分类号：
摘要：
Epilepsy raises special concern in women during pregnancy. Antiepileptic drugs are known to induce major and minor malformations in the foetus. Aim of the study was to find an association between maternal serum alpha fetoprotein levels, foetal abnormalities and antiepileptic drugs mediated teratogenicity. Maternal serum alpha feto protein levels, kidney and liver function tests in age matched normal pregnant women and seizure free epileptic pregnant women during 12 - 14 weeks of gestation were estimated. Cases were subjected to ultrasonography at 11th-14th week of pregnancy and again at 20th week of pregnancy. maternal serum alfa feto protein was assayed by a specific Electro Chemiluminescence Immuno Assay test. There was no significant difference in kidney and liver function tests in cases as compared to controls. There were elevated levels of alpha feto protein in cases as compared to controls but this was not statistically significant. No anomalies were detected in ultrasound reports. Most women had normal full term delivery with healthy children but of low birth weight. No correlation was seen between maternal serum alfa feto protein levels and antiepileptic drug leading to teratogenesis.
引用
收藏
页码：267 / 271
页数：4
相关论文
共 30 条
  • [1] Sridaran R., Murthy B.N., Prevalence and pattern of epilepsy in India, Epilepsia, 40, pp. 631-636, (1999)
  • [2] Gaily E., Kanota-Sorsa E., Hillesmaa V., Normal intelligence in children with prenatal exposure to carbamazepine, Neurology, 62, pp. 28-32, (2004)
  • [3] Meador K.J., Zupang M.L., Neurodeveopmental outcome of children born to mothers with epilepsy, Cleve Clin J Med, 71, pp. 38-41, (2004)
  • [4] Marrow J.J., Graig J.J., Antiepileptic drugs in pregnancy. Current safety and other issues, Exp Opin Pharmacother, 4, pp. 445-456, (2003)
  • [5] Knight A.H., Rhind E.G., Epilepsy and pregnancy. A study of 153 pregnancies in 59 patients, Epilepsia, 16, pp. 99-110, (1975)
  • [6] Yerby M.S., Pregnancy and epilepsy, Epilepsia, 32, pp. 51-59, (1991)
  • [7] Costa A., Lopes-Cendes I., Guerreiro C.A., Seizure frequency during pregnancy and the puerperium, Inter J Gynaecol Obstet, 88, pp. 148-149, (2005)
  • [8] Batino D., Binclli S., Caccamo M.L., Malformations in the offspring's of 305 epileptic women, a prospective study, Acta. Neurol Scand, 85, pp. 204-207, (1992)
  • [9] Kaneko S., Battino D., Andermann E., Wada K., Kan R., Takeda A., Nakane Y., Et al., Congenital malformations due to antiepileptic drugs, Epilepsy Res, 33, pp. 145-158, (1999)
  • [10] Artama M.A., Raudaskoski T., Isojarvi J.I.T., Raitanen J., Auvinen A., Antileptic drug use of women with epilepsy and congenital malformation of offspring, Neurology, 64, pp. 1874-1878, (2005)
123